Market Highlights and Obesity Drug Insights

This chapter explores the recent surge in stock market indices, including all-time highs for the Dow and S&P 500, while also analyzing Amgen's disappointing trial results for its obesity drug. It further examines the impact of new healthcare proposals on obesity medication and expert perspectives on future trial enhancements.